Biotech Values

[dav1234]

ImmunoCellular +13.2%, wins orphan drug status for ICT-107 in the EU
ImmunoCellular Therapeutics (IMUC +13.2%) says it has been granted orphan drug designation for ICT-107 for the treatment of patients with glioblastoma.Granting of orphan drug status in the EU provides sponsor companies with incentives, including a 10-year period of market exclusivity, access to a centralized review process, trial design assistance and scientific advice during product development, fee reductions, and tax incentives.IMUC already had received orphan designation for ICT-107 in glioblastoma in the U.S.